ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2026
Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medications targeting calcitonin gene-related peptide (CGRP) have been approved for both acute treatment and prevention of migraines. Controversy surrounds the concomitant use of these agents for these 2 purposes, given their similar mechanisms of action and the limited data available to support concurrent use. Methods: A medication use evaluation was performed using electronic health record prescription records. The primary objective was to assess the safety of dual CGRP-targeting therapies when used for both the prevention and acute treatment of migraines. A secondary exploratory objective was to assess the efficacy of combination treatment regimens. Patients were included if they had a documented diagnosis of migraine and were concomitantly using a preventive CGRP-targeting regimen and a gepant for acute migraine treatment between April 1, 2023, and January 31, 2025. Results: The analysis included 89 patients. Most were female (60.7%), with a mean age of 46.8 years and a diagnosis of chronic migraines (76.4%). There were 149 unique dual CGRP-targeting regimens identified and included in the safety analysis, 59 of which were eligible for the exploratory efficacy analysis. No new or concerning adverse effects were identified. Only 7 adverse drug reactions were reported by patients and documented. The efficacy analysis revealed no median change in migraine intensity (0.0, Conclusions: The use of concomitant dual CGRP-targeting agents for migraine treatment and prevention appears to be safe and well tolerated. Efficacy data were limited in this study; randomized controlled trials are needed to fully assess this endpoint.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.